TAMMY TAYLOR-BUFFORD: Open Payments
NPI 1972538718 · CLARKSDALE, MS. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$480 in 20 payments from 7 companies in 2025. Trend: 2023 $1,793 · 2024 $722 · 2025 $480
Food & beverage: $480
| Company | Payments | Amount |
|---|---|---|
| Novo Nordisk Inc | 4 | $138 |
| AstraZeneca Pharmaceuticals LP | 6 | $107 |
| Amgen Inc. | 2 | $90 |
| Lilly USA, LLC | 4 | $71 |
| Sumitomo Pharma America, Inc. | 2 | $34 |
| ABBVIE INC. | 1 | $24 |
| Aimmune Therapeutics, Inc. | 1 | $16 |
Products named: Ozempic, FARXIGA, REPATHA, JARDIANCE, GEMTESA, CREON, AIRSUPRA, ZENPEP.
Industry payments across MS — which companies pay providers there.
